Novo Nordisk A/S $NVO Holdings Decreased by Verdence Capital Advisors LLC

Verdence Capital Advisors LLC decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 84.0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 5,394 shares of the company’s stock after selling 28,409 shares during the quarter. Verdence Capital Advisors LLC’s holdings in Novo Nordisk A/S were worth $274,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Capital International Investors grew its holdings in shares of Novo Nordisk A/S by 52.4% during the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after buying an additional 6,092,192 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Novo Nordisk A/S by 4,190.8% during the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after buying an additional 13,658,867 shares in the last quarter. Folketrygdfondet grew its holdings in shares of Novo Nordisk A/S by 1.2% during the third quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock valued at $566,659,000 after buying an additional 117,370 shares in the last quarter. State Street Corp grew its holdings in shares of Novo Nordisk A/S by 1.0% during the third quarter. State Street Corp now owns 6,106,836 shares of the company’s stock valued at $340,125,000 after buying an additional 59,153 shares in the last quarter. Finally, Boston Partners purchased a new position in shares of Novo Nordisk A/S during the third quarter valued at $310,199,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo launched a share repurchase programme (part of up to DKK 15bn across 12 months), a direct capital-return measure that can support the share price and EPS. Share repurchase programme
• Positive Sentiment: New clinical and real-world Wegovy data (including higher‑dose Wegovy and the Wegovy pill) will be presented at the European Congress on Obesity, supporting the long‑term obesity franchise and next‑generation combo therapies. ECO data presentation
• Positive Sentiment: Wegovy pill (oral semaglutide) is tracking ahead of Lilly’s oral rival at a similar launch stage, suggesting durable prescription momentum for Novo’s oral format. This helps offset some injectable pricing pressure. Wegovy pill prescription data
• Positive Sentiment: Regulatory/pipeline wins: Novo received Fast Track designation for coramitug (PRX004) in ATTR amyloidosis and reported encouraging late‑stage results in other rare-disease assets, diversifying growth beyond GLP‑1s. Fast Track and pipeline news
• Neutral Sentiment: Analysts and commentators are debating whether current Novo share pricing accurately reflects recent volatility, weighing secular GLP‑1 growth vs. near‑term headwinds; this keeps valuation scrutiny high. Valuation and market debate
• Neutral Sentiment: Novo is pushing oral Ozempic and pediatric label expansions as strategic levers to counter slowing demand and pricing pressure, but execution and uptake remain to be proven. Oral Ozempic and label expansion analysis
• Negative Sentiment: Health Canada approved the first generic version of Ozempic (Dr Reddy’s), a direct pricing and market‑share threat for Novo’s semaglutide franchise in Canada that increases global generics risk. Health Canada generic approval
• Negative Sentiment: Competitor advances: Boehringer/Zealand’s survodutide showed meaningful weight loss in a late‑stage trial, and Eli Lilly’s oral Foundayo is gaining prescriptions — both raise competitive pressure on Novo’s obesity franchise. Boehringer/Zealand trial
• Negative Sentiment: Broader entrance into GLP‑1 distribution (e.g., Amazon/other newcomers) and growing competition could pressure pricing and margins over time. Amazon GLP‑1 entrance

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on NVO. Sanford C. Bernstein began coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target on the stock. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Kepler Capital Markets downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Four investment analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $41.18 on Wednesday. The business has a 50 day moving average price of $38.80 and a 200 day moving average price of $47.41. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The company has a market cap of $183.87 billion, a price-to-earnings ratio of 11.87, a PEG ratio of 9.80 and a beta of 0.73. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Research analysts predict that Novo Nordisk A/S will post 3.34 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently announced a dividend, which was paid on Wednesday, April 8th. Investors of record on Monday, March 30th were given a dividend of $1.2751 per share. The ex-dividend date of this dividend was Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S’s payout ratio is 50.43%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.